Avicenne Invest S.A. and GCG Investments exit Futuremeds Ltd cap table

Futuremeds Ltd, a Wirral-based clinical trial service provider founded in 2020, has seen four shareholders exit its cap table according to its latest confirmation statement for the period ending 16 May 2026. The most significant departure is Avicenne Invest S.A., which previously held 1,516 C Ordinary shares.

Other exits include GCG Investments Limited, which held 1,027 A Ordinary shares. GCG Investments Limited is also a shareholder in HGL Private Capital Limited. Beauport G&N Limited has also departed the cap table, having previously held 996 A Ordinary shares. Finally, Roost Assets Ltd exited its position of 66 A Ordinary shares.

Futuremeds Ltd operates as a European dedicated research site network and Decentralized Clinical Trial service provider. The company delivers patient-centric, high-quality clinical trials to pharmaceutical companies, sponsors, and Contract Research Organizations to accelerate patient access to new treatments. These changes to the shareholder register were recorded in the filing made on 21 June 2026. The departures represent a change in the company ownership structure during the last twelve month period.